MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE:...
207
Transcript of MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE:...
![Page 1: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/1.jpg)
![Page 2: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/2.jpg)
![Page 3: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/3.jpg)
![Page 4: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/4.jpg)
![Page 5: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/5.jpg)
![Page 6: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/6.jpg)
![Page 7: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/7.jpg)
![Page 8: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/8.jpg)
![Page 9: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/9.jpg)
![Page 10: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/10.jpg)
![Page 11: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/11.jpg)
![Page 12: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/12.jpg)
![Page 13: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/13.jpg)
![Page 14: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/14.jpg)
![Page 15: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/15.jpg)
![Page 16: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/16.jpg)
![Page 17: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/17.jpg)
![Page 18: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/18.jpg)
![Page 19: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/19.jpg)
![Page 20: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/20.jpg)
![Page 21: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/21.jpg)
![Page 22: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/22.jpg)
![Page 23: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/23.jpg)
![Page 24: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/24.jpg)
![Page 25: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/25.jpg)
![Page 26: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/26.jpg)
![Page 27: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/27.jpg)
![Page 28: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/28.jpg)
![Page 29: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/29.jpg)
![Page 30: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/30.jpg)
![Page 31: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/31.jpg)
![Page 32: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/32.jpg)
![Page 33: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/33.jpg)
![Page 34: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/34.jpg)
![Page 35: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/35.jpg)
![Page 36: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/36.jpg)
![Page 37: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/37.jpg)
![Page 38: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/38.jpg)
![Page 39: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/39.jpg)
![Page 40: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/40.jpg)
![Page 41: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/41.jpg)
![Page 42: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/42.jpg)
![Page 43: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/43.jpg)
![Page 44: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/44.jpg)
![Page 45: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/45.jpg)
![Page 46: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/46.jpg)
![Page 47: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/47.jpg)
![Page 48: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/48.jpg)
![Page 49: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/49.jpg)
![Page 50: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/50.jpg)
![Page 51: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/51.jpg)
![Page 52: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/52.jpg)
![Page 53: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/53.jpg)
![Page 54: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/54.jpg)
![Page 55: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/55.jpg)
![Page 56: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/56.jpg)
![Page 57: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/57.jpg)
![Page 58: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/58.jpg)
![Page 59: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/59.jpg)
![Page 60: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/60.jpg)
![Page 61: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/61.jpg)
![Page 62: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/62.jpg)
![Page 63: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/63.jpg)
![Page 64: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/64.jpg)
![Page 65: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/65.jpg)
![Page 66: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/66.jpg)
![Page 67: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/67.jpg)
![Page 68: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/68.jpg)
![Page 69: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/69.jpg)
![Page 70: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/70.jpg)
![Page 71: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/71.jpg)
![Page 72: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/72.jpg)
![Page 73: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/73.jpg)
![Page 74: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/74.jpg)
![Page 75: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/75.jpg)
![Page 76: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/76.jpg)
![Page 77: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/77.jpg)
![Page 78: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/78.jpg)
![Page 79: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/79.jpg)
![Page 80: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/80.jpg)
![Page 81: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/81.jpg)
![Page 82: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/82.jpg)
![Page 83: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/83.jpg)
![Page 84: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/84.jpg)
![Page 85: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/85.jpg)
![Page 86: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/86.jpg)
![Page 87: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/87.jpg)
![Page 88: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/88.jpg)
![Page 89: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/89.jpg)
![Page 90: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/90.jpg)
![Page 91: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/91.jpg)
![Page 92: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/92.jpg)
![Page 93: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/93.jpg)
![Page 94: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/94.jpg)
![Page 95: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/95.jpg)
![Page 96: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/96.jpg)
![Page 97: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/97.jpg)
![Page 98: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/98.jpg)
![Page 99: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/99.jpg)
![Page 100: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/100.jpg)
![Page 101: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/101.jpg)
![Page 102: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/102.jpg)
![Page 103: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/103.jpg)
![Page 104: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/104.jpg)
![Page 105: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/105.jpg)
![Page 106: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/106.jpg)
![Page 107: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/107.jpg)
![Page 108: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/108.jpg)
![Page 109: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/109.jpg)
![Page 110: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/110.jpg)
![Page 111: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/111.jpg)
![Page 112: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/112.jpg)
![Page 113: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/113.jpg)
![Page 114: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/114.jpg)
![Page 115: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/115.jpg)
![Page 116: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/116.jpg)
![Page 117: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/117.jpg)
![Page 118: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/118.jpg)
![Page 119: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/119.jpg)
![Page 120: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/120.jpg)
![Page 121: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/121.jpg)
![Page 122: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/122.jpg)
![Page 123: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/123.jpg)
![Page 124: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/124.jpg)
![Page 125: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/125.jpg)
![Page 126: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/126.jpg)
![Page 127: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/127.jpg)
![Page 128: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/128.jpg)
![Page 129: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/129.jpg)
![Page 130: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/130.jpg)
![Page 131: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/131.jpg)
![Page 132: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/132.jpg)
![Page 133: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/133.jpg)
![Page 134: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/134.jpg)
![Page 135: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/135.jpg)
![Page 136: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/136.jpg)
![Page 137: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/137.jpg)
![Page 138: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/138.jpg)
![Page 139: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/139.jpg)
![Page 140: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/140.jpg)
![Page 141: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/141.jpg)
![Page 142: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/142.jpg)
![Page 143: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/143.jpg)
![Page 144: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/144.jpg)
![Page 145: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/145.jpg)
![Page 146: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/146.jpg)
![Page 147: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/147.jpg)
![Page 148: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/148.jpg)
![Page 149: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/149.jpg)
![Page 150: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/150.jpg)
![Page 151: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/151.jpg)
![Page 152: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/152.jpg)
![Page 153: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/153.jpg)
![Page 154: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/154.jpg)
![Page 155: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/155.jpg)
![Page 156: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/156.jpg)
![Page 157: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/157.jpg)
![Page 158: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/158.jpg)
![Page 159: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/159.jpg)
![Page 160: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/160.jpg)
![Page 161: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/161.jpg)
![Page 162: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/162.jpg)
![Page 163: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/163.jpg)
![Page 164: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/164.jpg)
![Page 165: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/165.jpg)
![Page 166: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/166.jpg)
![Page 167: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/167.jpg)
![Page 168: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/168.jpg)
![Page 169: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/169.jpg)
![Page 170: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/170.jpg)
![Page 171: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/171.jpg)
![Page 172: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/172.jpg)
![Page 173: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/173.jpg)
![Page 174: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/174.jpg)
![Page 175: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/175.jpg)
![Page 176: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/176.jpg)
![Page 177: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/177.jpg)
![Page 178: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/178.jpg)
![Page 179: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/179.jpg)
![Page 180: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/180.jpg)
![Page 181: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/181.jpg)
![Page 182: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/182.jpg)
![Page 183: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/183.jpg)
![Page 184: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/184.jpg)
![Page 185: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/185.jpg)
![Page 186: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/186.jpg)
![Page 187: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/187.jpg)
![Page 188: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/188.jpg)
![Page 189: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/189.jpg)
![Page 190: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/190.jpg)
![Page 191: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/191.jpg)
![Page 192: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/192.jpg)
![Page 193: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/193.jpg)
![Page 194: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/194.jpg)
![Page 195: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/195.jpg)
![Page 196: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/196.jpg)
![Page 197: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/197.jpg)
![Page 198: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/198.jpg)
![Page 199: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/199.jpg)
![Page 200: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/200.jpg)
![Page 201: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/201.jpg)
![Page 202: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/202.jpg)
![Page 203: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/203.jpg)
![Page 204: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/204.jpg)
![Page 205: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/205.jpg)
![Page 206: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/206.jpg)
![Page 207: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9](https://reader034.fdocuments.us/reader034/viewer/2022052101/603af6759e196a10bb6a06bd/html5/thumbnails/207.jpg)